{"url":"https://lda.senate.gov/api/v1/filings/e528d1ef-e0d0-41c5-b93a-42d2ab2e2696/","filing_uuid":"e528d1ef-e0d0-41c5-b93a-42d2ab2e2696","filing_type":"Q4","filing_type_display":"4th Quarter - Report","filing_year":2022,"filing_period":"fourth_quarter","filing_period_display":"4th Quarter (Oct 1 - Dec 31)","filing_document_url":"https://lda.senate.gov/filings/public/filing/e528d1ef-e0d0-41c5-b93a-42d2ab2e2696/print/","filing_document_content_type":"text/html","income":"60000.00","expenses":null,"expenses_method":null,"expenses_method_display":null,"posted_by_name":"Beth Anne Cole","dt_posted":"2023-01-14T15:16:59-05:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"880 New Jersey Avenue, SE","registrant_address_2":"Unit 927","registrant_different_address":false,"registrant_city":"Washington","registrant_state":"DC","registrant_zip":"20003","registrant":{"id":401105121,"url":"https://lda.senate.gov/api/v1/registrants/401105121/","house_registrant_id":44305,"name":"MARSHALL & POPP, LLC","description":"​Government affairs and consulting firm.","address_1":"611 2nd Street, NE","address_2":"Suite 1","address_3":null,"address_4":null,"city":"Washington","state":"DC","state_display":"District of Columbia","zip":"20002","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"BETH ANNE COLE","contact_telephone":"+1 202-321-1811","dt_updated":"2026-07-13T16:40:37.032909-04:00"},"client":{"id":211744,"url":"https://lda.senate.gov/api/v1/clients/211744/","client_id":241,"name":"BUTTERFLY NETWORK, INC.","general_description":"Medical device manufacturer and service provider.","client_government_entity":false,"client_self_select":null,"state":"CT","state_display":"Connecticut","country":"US","country_display":"United States of America","ppb_state":"CT","ppb_state_display":"Connecticut","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2021-08-01"},"lobbying_activities":[{"general_issue_code":"MAN","general_issue_code_display":"Manufacturing","description":"Issues related to medical device manufacturing / insurance / technology, including S.3799, the PREVENT Pandemics Act, and H.R.2617, Consolidated Appropriations Act, 2023. Issues related to FDA regulation of medical devices, including including S.4348, Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act, H.R.6833, Making continuing appropriations for fiscal year 2023, and H.R.2617, Consolidated Appropriations Act, 2023.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":70852,"prefix":null,"prefix_display":null,"first_name":"HAZEN","nickname":null,"middle_name":"CLAY","last_name":"MARSHALL","suffix":null,"suffix_display":null},"covered_position":"Policy Director-Senate Majority Leader Mitch McConnell; Staff Director, Senate Budget Committee-Senator Don Nickles; Deputy Chief of Staff/Economist, Office of Assistant Majority Leader-Senator Don Nickles; Legislative Assistant-Senator Don Nickles","new":false},{"lobbyist":{"id":70067,"prefix":null,"prefix_display":null,"first_name":"MONICA","nickname":null,"middle_name":null,"last_name":"POPP","suffix":null,"suffix_display":null},"covered_position":"Chief of Staff/Deputy Chief of Staff, Office of Senate Republican Whip John Cornyn; Professional Staff Member, U.S. House of Representatives-Energy & Commerce Committee; Legislative Assistant, Senator Jim DeMint","new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"MED","general_issue_code_display":"Medical/Disease Research/Clinical Labs","description":"Issues related to medical device manufacturing / insurance / technology, including S.3799, the PREVENT Pandemics Act, and H.R.2617, Consolidated Appropriations Act, 2023. Issues related to FDA regulation of medical devices, including including S.4348, Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act, H.R.6833, Making continuing appropriations for fiscal year 2023, and H.R.2617, Consolidated Appropriations Act, 2023.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":70852,"prefix":null,"prefix_display":null,"first_name":"HAZEN","nickname":null,"middle_name":"CLAY","last_name":"MARSHALL","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":70067,"prefix":null,"prefix_display":null,"first_name":"MONICA","nickname":null,"middle_name":null,"last_name":"POPP","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"PHA","general_issue_code_display":"Pharmacy","description":"Issues related to medical device manufacturing / insurance / technology, including S.3799, the PREVENT Pandemics Act, and H.R.2617, Consolidated Appropriations Act, 2023. Issues related to FDA regulation of medical devices, including including S.4348, Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act, H.R.6833, Making continuing appropriations for fiscal year 2023, and H.R.2617, Consolidated Appropriations Act, 2023.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":70852,"prefix":null,"prefix_display":null,"first_name":"HAZEN","nickname":null,"middle_name":"CLAY","last_name":"MARSHALL","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":70067,"prefix":null,"prefix_display":null,"first_name":"MONICA","nickname":null,"middle_name":null,"last_name":"POPP","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"SCI","general_issue_code_display":"Science/Technology","description":"Issues related to medical device manufacturing / insurance / technology, including S.3799, the PREVENT Pandemics Act, and H.R.2617, Consolidated Appropriations Act, 2023. Issues related to FDA regulation of medical devices, including including S.4348, Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act, H.R.6833, Making continuing appropriations for fiscal year 2023, and H.R.2617, Consolidated Appropriations Act, 2023.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":70852,"prefix":null,"prefix_display":null,"first_name":"HAZEN","nickname":null,"middle_name":"CLAY","last_name":"MARSHALL","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":70067,"prefix":null,"prefix_display":null,"first_name":"MONICA","nickname":null,"middle_name":null,"last_name":"POPP","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]}